About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study
(regulatory)
Read more
Guard Therapeutics to present Phase 2b POINTER study design at scientific conference
Read more
Guard Therapeutics announces changes in number of shares and votes
(regulatory)
Read more
Press releases
27 May 2025 · Regulatory information
Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study
Read more
21 May 2025
Guard Therapeutics to present Phase 2b POINTER study design at scientific conference
Read more
11 Apr 2025 · Regulatory information
Guard Therapeutics announces changes in number of shares and votes
Read more
04 Apr 2025 · Regulatory information
Guard Therapeutics announces outcome of the rights issue
Read more
Show more
In focus
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
30 Jan 2024 / Presentation
Guard Therapeutics R&D update January 30, 2024
Read more
Show more
Upcoming events
04 Jun 2025
Guard presents at the 62nd ERA Congress, Vienna, June 4-7
Read more
16 Jun 2025
Guard attends the Bio International, Boston, June 16-19
Read more
21 Aug 2025
Interim report January-June 2025
Read more
01 Sep 2025
Guard presents at DNB Carnegie Small Cap Day September 1st
Show more
Event calendar
/
Financial calendar